Table 1.

Summary of the major findings of the studies investigating the effect of allergen immunotherapy in local allergic rhinitis; RDBPC: randomized, double-blind, placebo controlled; CSMS: combined symptom and medication score; sIgG₄/IgG/IgE: allergen-specific IgG₄/IgG/IgE; STU, DPP and AUM are standardization units used by ALK, Leti and Hal Allergy, respectively.

	Design	Comparator	Allergen Immunotherapy Extract	Allergen Dose	Primary Outcome	Rhinoconjunctivitis Symptom Score	Conjunctival Symptom Score	Medication Free Days	Quality of Life	Allergen Tolerated in the Nasal Challenge	Serun sIgG4	Nasal sIgE
Rondon, J Allergy Clin Immunol 2011 [18]	Open Observational	Medication only	Pangramin Plus © Grass pollen mix ALK	8 mL/month (1000 STU/mL)	Nasal tolerance to the allergen AND serum sIgG	Decrease	Not measured	Increase	Not measured	Increase	Increase (sIgG)	Not measured
Rondon, Allergy 2016 [19]	RDBPC	Placebo	Pangramin Plus © Dermatophagoides pteronyssinus ALK	8 mL/month (1000 STU/mL)	CSMS, symptom score, medication score, medication free days	Decrease	Not measured	Increase	Not measured	Increase	Increase	Not measured
Rondon, Allergy 2018 [20]	RDBPC	Placebo	Depigoid © Phleum pretense Laborat. Leti SL	5 mL/month (1000 DPP/mL)	CSMS	Decrease	Decrease	Increase	Improvement	Increase	Increase	Not measured
Bozek, Ann Allergy Asthma Immunol 2018 [79]	RDBPC	Placebo	Purethal© Betula verrucosa HAL Allergy SLU	5 mL/month (20000 AUM/mL)	CSMS	Decrease	Not measured	Increase	Improvement	Not measured	Increase	Decrease